Corona Vaccine: Corbavax vaccine will stop the speed of the Covid-19 virus, and is effective in increasing immunity

Posted on 19th Oct 2022 by rohit kumar

The Ministry of Health has issued an alert regarding the new sub-variant BF.7 of the coronavirus found in India. Union Health Minister Mansukh Mandaviya held a high-level meeting on Tuesday after the first case of this variant of Omicron was reported in the country. Meanwhile, the ministry is going to re-emphasize corona vaccination. So that people can be protected from this variant. The heterologous booster vaccine is in discussion amid rising infections. This vaccine is believed to be effective in the fight against various variants of the coronavirus. Many countries these days are using the homologous vaccine as a booster dose. Many countries like America, Britain, and Israel have approved The Heterologous Booster for emergencies.

 

A recent Lancet study on the effectiveness of heterologous and homologous boosters found that heterologous boosters provide greater protection than homologous boosters. In the first cell immunity and secondly in neutralizing antibodies, giving a heterologous booster vaccine showed an increase in immunity. Recently the Government of India has allowed the heterologous booster shot for all adults as an emergency use of the Covid-19 vaccine Corbevax. Biologics E's Corbevax is safe and as a heterologous booster vaccine, antibodies against many different variants of COVID-19 are effective in better destruction of the virus.

 

Dr. M. Raja Rao, Medical Superintendent of Gandhi Hospital, says that India has managed the pandemic and the ensuing health crisis with coordinated efforts between the government, industry, and healthcare providers. An effective vaccination plan has prevented the wave of COVID-19 from progressing further. However, given the peculiar nature of the disease and the mutation of the virus, an additional layer of protection against infection is needed. The development of the heterologous booster vaccine is a step towards a more scientific and timely immunization plan. A heterologous is the preferred choice for booster doses, as it produces effective results against the variants (Delta and Omicron) and improves the cellular immune response (notably the TH-1-related response).

 

In addition, Corbevax can be administered as a booster in adults over six months after two doses of Covaccine or Covishield. Administering the Corbevax vaccine as a heterologous booster dose significantly increases immunity and provides better protection for people who have already received Covishield or two doses of Covaxin. BE conducted a Phase III placebo-controlled heterologous booster clinical trial at multiple centers among 416 fully vaccinated people aged 18 to 80 years. The Corbevax heterologous booster achieved a 5.5 to 6.7-fold (geometric value multiplier) increase in neutralizing antibody titers.

 

People were also screened for destroying antibodies to Omicron and showed a significant increase in antibody counts after taking Corbevax as a heterologous booster vaccine. In about 75 percent to 91 percent of these people, antibodies were seen to be successful in destroying the Omicron variant. This trial demonstrated that the Corbevax booster dose is safe and well tolerated, with no serious or grade-3 adverse outcomes or specific events of special interest occurring over three months.

 

Also Read: Omicron BF.7: Knocking of a new variant of Omicron in India, know how dangerous BF.7 is already